Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Subhasree Kar

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Regeneron Pharmaceuticals, Inc. (REGN), is a biotechnology company headquartered in Tarrytown, New York, with a market cap of around $82.6 billion. The company specializes in discovering, developing, manufacturing, and commercializing transformative medicines across a broad range of serious diseases, including eye diseases, allergy and inflammation, cancer, cardiovascular, neurological, infectious, hematologic, and rare diseases.

Companies with a market cap of $10 billion or more are typically classified as “large-cap” stocks, and Regeneron Pharmaceuticals comfortably falls within this group. The biotechnology leader is widely recognized for its diverse portfolio of innovative medicines and its development of breakthrough therapies.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.